½ÃÀ庸°í¼­
»óǰÄÚµå
1587339

¹Ý·Áµ¿¹° ¼ö¼úÈÄ ÅëÁõ °ü¸® Ä¡·áÁ¦ ½ÃÀå : Á¦Ç° À¯Çüº°, µ¿¹° À¯Çüº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Companion Animal Postoperative Pain Management Therapeutics Market by Product (Anesthetics, NSAIDs, Opioids), Animal Type (Canine, Feline) - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 183 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¹Ý·Áµ¿¹° ¼ö¼úÈÄ ÅëÁõ °ü¸® Ä¡·áÁ¦ ½ÃÀåÀº 2023³â¿¡ 1¾ï 3,592¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 1¾ï 4,946¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 10.05%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 2¾ï 6,574¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¹Ý·Áµ¿¹° ¼ö¼úÈÄ ÅëÁõ °ü¸® Ä¡·áÁ¦ ½ÃÀåÀº ¼ö¼úÈÄ µ¿¹°ÀÇ ÅëÁõÀ» ¿ÏÈ­Çϱâ À§ÇØ °í¾ÈµÈ Á¦Ç°¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖÀ¸¸ç, ¾à¹° ¿ä¹ý, Ä¡·á¹ý, ÀÇ·á±â±â µîÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ Ä¡·áÁ¦ÀÇ Çʿ伺Àº µ¿¹°ÀÇ º¹Áö¸¦ º¸ÀåÇϱâ À§ÇÑ ¼öÀÇ»ç¿Í ¹Ý·Áµ¿¹° º¸È£ÀÚÀÇ À±¸®Àû Àǹ«¿Í µ¿¹° ÅëÁõ °ü¸®ÀÇ Çʿ伺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó »ý°Ü³µ½À´Ï´Ù. Ä¡·á¿¡´Â Á¤Çü¿Ü°ú ¼ö¼ú, ¿¬Á¶Á÷ ½Ã¼ú ¹× ±âŸ ¼öÀÇÇÐÀû ¼ö¼úÈÄ Ä¡·á°¡ Æ÷ÇԵǸç, ÃÖÁ¾ »ç¿ëÀÚ´Â µ¿¹°º´¿ø, º´¿ø ¹× ¹Ý·Áµ¿¹° º¸È£ÀÚÀÔ´Ï´Ù. ¼ºÀå ¿äÀÎÀ¸·Î´Â ¹Ý·Áµ¿¹°ÀÇ Àΰ£È­ Ãß¼¼·Î ÀÎÇÑ µ¿¹° °Ç°­°ü¸®¿¡ ´ëÇÑ ÁöÃâ Áõ°¡, ¼ö¼úÈÄ °ü¸®ÀÇ Á߿伺À» °­Á¶ÇÏ´Â ¼öÀÇÇÐ ¹ßÀü µîÀÌ ÀÖ½À´Ï´Ù. ¹Ý·Áµ¿¹° Àα¸ Áõ°¡¿Í ¾à¹° Á¦ÇüÀÇ Çõ½ÅÀ¸·Î ÀÎÇØ ½ÃÀåÀº ´õ¿í °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ºñħ½ÀÀû ÅëÁõ °ü¸® ¼Ö·ç¼Ç °³¹ß ¹× ¿ø°Ý ÀǷḦ Ȱ¿ëÇÑ ¿ø°Ý ÅëÁõ °ü¸® »ó´ã¿¡ ºñÁî´Ï½º ±âȸ°¡ ÀÖ½À´Ï´Ù. ¿¬±¸°³¹ß º¸Á¶±ÝÀ» ÅëÇÑ ¼öÀǰú´ëÇаúÀÇ Çù·Âµµ °æÀï ¿ìÀ§¸¦ °¡Á®´Ù ÁÙ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ±ÔÁ¦ ¹®Á¦, ³ôÀº ½Å¾à °³¹ß ºñ¿ë, ƯÁ¤ Áö¿ª¿¡¼­ÀÇ µ¿¹° ÀÇ·á Á¢±Ù¼º Á¦ÇÑ µîÀÇ Á¦¾àÀÌ ½ÃÀå ¼ºÀåÀÇ °É¸²µ¹·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, µ¿¹°ÀÇ ¼ö¼úÈÄ ÅëÁõ °ü¸®¿¡ ´ëÇÑ Ç¥ÁØÈ­µÈ °¡À̵å¶óÀÎÀÌ ¾ø±â ¶§¹®¿¡ Ä¡·áÀÇ ÆíÂ÷°¡ ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¼ú Çõ½Å ¹× ¿¬±¸ ºÐ¾ß¿¡´Â CBD ¹× ·¹ÀÌÀú Ä¡·á¿Í °°Àº ´ëü ¿ä¹ýÀÇ È°¿ë°ú ÅëÁõ °ü¸®¿¡ ´ëÇÑ °³º°È­µÈ ÀÇ·á Á¢±Ù¹ýÀÇ È¿°ú¿¡ ´ëÇÑ Å½»öÀÌ Æ÷ÇԵ˴ϴÙ. Áö¿ªº° ¿ä±¸¿Í ¼±È£µµ¸¦ ÆÄ¾ÇÇÏ´Â °Íµµ ¸ÂÃãÇü Á¦Ç° °³¹ßÀÇ ¿øµ¿·ÂÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ½ÃÀåÀº ¿ªµ¿ÀûÀ̸ç, ÀüÅëÀûÀÎ ¾à¸®ÇÐÀû Ä¡·á¿Í Çõ½ÅÀû Ä¡·á¹ýÀ» °áÇÕÇÑ º¹ÇÕÀû ÅëÁõ °ü¸® Á¢±Ù¹ýÀÌ Æ®·»µå·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù. µû¶ó¼­ ÇÑ¹ß ¾Õ¼­ ³ª°¡±â À§Çؼ­´Â ±ÔÁ¦ µ¿ÇâÀ» Áö¼ÓÀûÀ¸·Î ¸ð´ÏÅ͸µÇϰí, »õ·Î¿î ÅëÁõ °ü¸® ¼Ö·ç¼ÇÀÇ ¿¬±¸°³¹ß¿¡ ÅõÀÚÇϸç, Àü·«Àû ÆÄÆ®³Ê½ÊÀ» ÅëÇØ Á¦Ç° À¯Åë°ú ÀÎÁöµµ¸¦ ³ô¿©¾ß ÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 1¾ï 3,592¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 1¾ï 4,946¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 2¾ï 6,574¸¸ ´Þ·¯
CAGR(%) 10.05%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ¹Ý·Áµ¿¹° ¼ö¼úÈÄ ÅëÁõ °ü¸® Ä¡·áÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®¸¦ °ø°³ÇÕ´Ï´Ù.

¹Ý·Áµ¿¹° ¼ö¼úÈÄ ÅëÁõ °ü¸® Ä¡·áÁ¦ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ¿ÏÈ­Çϰí, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¹Ý·Áµ¿¹° »çÀ° ±ÞÁõ
    • ¹Ý·Áµ¿¹°ÀÇ Ä¡ÁÖÁúȯ À¯º´·ü »ó½Â
    • ¹Ý·Áµ¿¹° ¼ö¼úÀÇ ¼ºÀå
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • Ä¡·áÁ¦ÀÇ ³ôÀº ºñ¿ë
  • ½ÃÀå ±âȸ
    • È¿À²ÀûÀÎ ¼ö¼úÈÄ ÅëÁõ °ü¸® Ä¡·áÁ¦ °³¹ßÀ» À§ÇÑ ¿¬±¸ °³¹ß È®´ë
    • ¹Ý·Áµ¿¹° º¸Çè °³¼±
  • ½ÃÀå °úÁ¦
    • ½ÅÈï±¹¿¡¼­ÀÇ ÀÎÁöµµ ¹× °¡¿ë¼º Á¦ÇÑ

Portre's Five Forces: ¹Ý·Áµ¿¹° ¼ö¼úÈÄ ÅëÁõ °ü¸® Ä¡·áÁ¦ ½ÃÀå °ø·«À» À§ÇÑ Àü·«Àû µµ±¸

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¹Ý·Áµ¿¹° ¼ö¼úÈÄ ÅëÁõ °ü¸® Ä¡·áÁ¦ ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ·Â ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¹Ý·Áµ¿¹° ¼ö¼úÈÄ ÅëÁõ °ü¸® Ä¡·áÁ¦ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ÀÖ¾î ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ¹Ý·Áµ¿¹° ¼ö¼úÈÄ ÅëÁõ °ü¸® Ä¡·áÁ¦ ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

¹Ý·Áµ¿¹° ¼ö¼úÈÄ ÅëÁõ °ü¸® Ä¡·áÁ¦ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ ¾÷üµéÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ¹Ý·Áµ¿¹° ¼ö¼úÈÄ ÅëÁõ °ü¸® Ä¡·áÁ¦ ½ÃÀå¿¡¼­°ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¹Ý·Áµ¿¹° ¼ö¼úÈÄ ÅëÁõ °ü¸® Ä¡·áÁ¦ ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ ¹Ý·Áµ¿¹° ¼ö¼úÈÄ ÅëÁõ °ü¸® Ä¡·áÁ¦ ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§ÇÑ Àü·« ºÐ¼® ¹× Ãßõ ¹Ý·Áµ¿¹°

µ¿¹Ýµ¿¹° ¼ö¼úÈÄ ÅëÁõ °ü¸® Ä¡·áÁ¦ ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº °æÀï ȯ°æÀÇ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ ü°è¸¦ ±¸ÃàÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • PorterÀÇ Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ¹Ý·Áµ¿¹° ¼ö¼úÈÄ ÅëÁõ °ü¸® Ä¡·áÁ¦ ½ÃÀå : Á¦Ç°º°

  • ¸¶ÃëÁ¦
  • NSAIDs
  • ¿ÀÇÇ¿ÀÀ̵å

Á¦7Àå ¹Ý·Áµ¿¹° ¼ö¼úÈÄ ÅëÁõ °ü¸® Ä¡·áÁ¦ ½ÃÀå : µ¿¹° À¯Çüº°

  • °³
  • °í¾çÀÌ

Á¦8Àå ¾Æ¸Þ¸®Ä«ÀÇ ¹Ý·Áµ¿¹° ¼ö¼úÈÄ ÅëÁõ °ü¸® Ä¡·áÁ¦ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¹Ý·Áµ¿¹° ¼ö¼úÈÄ ÅëÁõ °ü¸® Ä¡·áÁ¦ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦10Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¹Ý·Áµ¿¹° ¼ö¼úÈÄ ÅëÁõ °ü¸® Ä¡·áÁ¦ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦11Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Addison Biological Laboratory Inc.
  • Assisi Animal Health
  • Bayer AG
  • Bimeda Animal Health
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Chanelle Pharma Group
  • Daiichi Sankyo Co. Ltd.
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Merck & Co.
  • Norbrook Laboratories
  • SAVA Vet
  • Vetoquinol S.A.
  • Virbac Group
  • Zoetis Inc.
LSH

The Companion Animal Postoperative Pain Management Therapeutics Market was valued at USD 135.92 million in 2023, expected to reach USD 149.46 million in 2024, and is projected to grow at a CAGR of 10.05%, to USD 265.74 million by 2030.

The Companion Animal Postoperative Pain Management Therapeutics market focuses on products designed to alleviate pain in animals after surgical procedures, encompassing medications, therapies, and medical devices. The necessity for these therapeutics is driven by the ethical obligation of veterinarians and pet owners to ensure animal welfare and the increasing awareness of animals' pain management needs. Applications include treatment post-orthopedic surgeries, soft-tissue procedures, and other veterinary surgeries, with end-users being veterinary clinics, hospitals, and pet owners. Growth factors include the rising trend of pet humanization, leading to increased spending on animal healthcare, and advances in veterinary medicine that highlight the importance of postoperative care. The market is further spurred by the expanding pet population and technological innovations in drug formulation. Opportunities lie in developing non-invasive pain management solutions and leveraging telemedicine for remote pain management consultations. Collaboration with veterinary schools for research and development grants can also provide competitive advantages. However, limitations such as regulatory challenges, high costs of new drug development, and limited access to veterinary care in certain regions pose challenges to market growth. Additionally, the lack of standardized guidelines for postoperative pain management in animals can create inconsistencies in treatment. Areas for innovation and research include the harnessing of alternative therapies like CBD and laser therapy, or exploring the efficacy of personalized medicine approaches for pain management. Understanding regional needs and preferences can also drive targeted product development. The market is dynamic, with a trend toward multi-modal pain management approaches that combine traditional pharmacological treatments with innovative therapies. Therefore, staying ahead requires continuous monitoring of regulatory trends, investing in R&D for novel pain management solutions, and adopting strategic partnerships to enhance product distribution and awareness.

KEY MARKET STATISTICS
Base Year [2023] USD 135.92 million
Estimated Year [2024] USD 149.46 million
Forecast Year [2030] USD 265.74 million
CAGR (%) 10.05%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Companion Animal Postoperative Pain Management Therapeutics Market

The Companion Animal Postoperative Pain Management Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Surge in companion animal ownership
    • Rising prevalence of periodontal diseases in aminals
    • Growth in pet surgical procedures
  • Market Restraints
    • High cost of therapeutics
  • Market Opportunities
    • Increasing R&D for development of efficient postoperative pain management therapeutics
    • Improvements in pet insurance policies
  • Market Challenges
    • Limited awareness and availability in developing economies

Porter's Five Forces: A Strategic Tool for Navigating the Companion Animal Postoperative Pain Management Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Companion Animal Postoperative Pain Management Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Companion Animal Postoperative Pain Management Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Companion Animal Postoperative Pain Management Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Companion Animal Postoperative Pain Management Therapeutics Market

A detailed market share analysis in the Companion Animal Postoperative Pain Management Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Companion Animal Postoperative Pain Management Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Companion Animal Postoperative Pain Management Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Companion Animal Postoperative Pain Management Therapeutics Market

A strategic analysis of the Companion Animal Postoperative Pain Management Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Companion Animal Postoperative Pain Management Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Addison Biological Laboratory Inc., Assisi Animal Health, Bayer AG, Bimeda Animal Health, Boehringer Ingelheim International GmbH, Ceva Sante Animale, Chanelle Pharma Group, Daiichi Sankyo Co. Ltd., Dechra Pharmaceuticals PLC, Elanco Animal Health Incorporated, Merck & Co., Norbrook Laboratories, SAVA Vet, Vetoquinol S.A., Virbac Group, and Zoetis Inc..

Market Segmentation & Coverage

This research report categorizes the Companion Animal Postoperative Pain Management Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Anesthetics, NSAIDs, and Opioids.
  • Based on Animal Type, market is studied across Canine and Feline.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Surge in companion animal ownership
      • 5.1.1.2. Rising prevalence of periodontal diseases in aminals
      • 5.1.1.3. Growth in pet surgical procedures
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing R&D for development of efficient postoperative pain management therapeutics
      • 5.1.3.2. Improvements in pet insurance policies
    • 5.1.4. Challenges
      • 5.1.4.1. Limited awareness and availability in developing economies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Companion Animal Postoperative Pain Management Therapeutics Market, by Product

  • 6.1. Introduction
  • 6.2. Anesthetics
  • 6.3. NSAIDs
  • 6.4. Opioids

7. Companion Animal Postoperative Pain Management Therapeutics Market, by Animal Type

  • 7.1. Introduction
  • 7.2. Canine
  • 7.3. Feline

8. Americas Companion Animal Postoperative Pain Management Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Companion Animal Postoperative Pain Management Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Companion Animal Postoperative Pain Management Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Addison Biological Laboratory Inc.
  • 2. Assisi Animal Health
  • 3. Bayer AG
  • 4. Bimeda Animal Health
  • 5. Boehringer Ingelheim International GmbH
  • 6. Ceva Sante Animale
  • 7. Chanelle Pharma Group
  • 8. Daiichi Sankyo Co. Ltd.
  • 9. Dechra Pharmaceuticals PLC
  • 10. Elanco Animal Health Incorporated
  • 11. Merck & Co.
  • 12. Norbrook Laboratories
  • 13. SAVA Vet
  • 14. Vetoquinol S.A.
  • 15. Virbac Group
  • 16. Zoetis Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦